NCT05846737招募中2 期
Safety and Efficiency of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT: a Prospective, Single-arm, Single-center, Phase II Study.
Institute of Hematology & Blood Diseases Hospital, China1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2023年5月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Safety and Tolerability
研究概览
简要总结
This study is a open-label, single-center Phase 2 study to evaluate the efficacy and safety of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT. A total of 40 subjects will be enrolled into this study.
详细描述
The study is a prospective, single-arm, single-centre, phase II study designed to evaluate the efficacy and safety of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT. Patients with detectable MRD after undergoing ASCT MRD will be enrolled in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •Participants with documented NDMM according to IMWG diagnostic criteria.
- •High-risk MM, as determined by R2-ISS（J Clin Oncol, 2022,40(29):3406-3418.）, Stage III or Stage IV.
- •Has received 3 to 6 cycles of induction therapy, followed by conditioning regimen and ASCT.
- •Screening must be completed within 100 days of ASCT.
- •For subjects receiving consolidation therapy after ASCT, screening must be completed within 60 days after consolidation therapy, and within 6 months after ASCT.
- •Detectable MRD using EuroFlow or NGS, at 100 days after ASCT (minimum sensitivity of 10-5).
- •All screening blood biochemistry: tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria: a.TBIL<1.5 x upper limit of normal (ULN) (<3 x ULN in patients with Gilbert's syndrome); b.AST and ALT <3 x ULN.; c. Creatinine clearance > 60mL/min (calculated using the Cockroft-Gault formula).
- •Routine blood tests (performed within 7 days, no RBC transfusion, no G-CSF/GM-CSF/platelet agonists, no drug correction within 14 days before screening, no PLT transfusion within 7 days) : WBC ≥ 1.5 x 109/L, ANC ≥ 1.0 x 109/L, Hb ≥ 85 g/L PLT ≥ 75 x 109/L (if BMPC < 50%) or PLT ≥ 50 x 109/L (if BMPC ≥ 50%).
- •Patients must be able to take prophylactic anticoagulant therapy as recommended by the study.
- •The woman is not breastfeeding, is not pregnant and agrees not to be pregnant during the study period and for the following 12 months. Male patients agreed that their spouse would not become pregnant during the study period and for 12 months thereafter.
排除标准
- •Primary plasma cell leukemia.
- •Documented active amyloidosis.
- •Multiple myeloma with central nervous system (CNS) invasion.
- •Has received maintenance therapy.
- •Prior exposure to any BCMA-targeted therapy or CAR-T therapy.
- •Patients with peripheral neuropathy greater than grade 2 or peripheral neuropathy greater than grade 2 with pain at baseline, regardless of whether they were currently receiving medical therapy.
- •Known intolerance, hypersensitivity, or contraindication to BCMA-CART cellular products.
- •Seropositive for human immunodeficiency virus (HIV).
- •Hepatitis B infection.
- •Hepatitis C infection.
- •Life expectancy of <3 months.
- •Women who are pregnant or breastfeeding.
- •Subjects had major surgery within 2 weeks before randomization (for example, general anesthesia), or is not fully recovered from the surgery, or surgery is arranged during study period.
- •Received live attenuated vaccine within 4 weeks prior to study treatment.
- •According to the researcher's judgment, any condition including but not limited to serious mental illness, medical illness, or other symptoms/conditions that may affect study treatment, compliance, or the capability of providing informed consent.
- •Necessary medication or supportive therapy is contraindicated with study treatment.
- •Any diseases or complications that may interfere with the study.
- •Patients are not willing to or cannot comply with study scheme.
结局指标
主要结局
Safety and Tolerability
时间窗: Up to 2 year
The incidence of treatment-emergent adverse events (TEAEs)
MRD-negativity rate
时间窗: 3 months after CAR-T cell infusion
Achieving undetectable MRD, as determined by NGF/NGS 3 months after CAR-T cell infusion
次要结局
- Complete response rate (CRR)(1 month after the CAR-T cell transfusion, after consolidation therapy)
- Progression free survival (PFS)(Up to 2 year)
- Overall Survival (OS)(Up to 5 year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma CellMultiple MyelomaNCT04272151Chongqing Precision Biotech Co., Ltd40
招募中
1 期
A Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseNeoplasm, Plasma CellMultiple Myeloma in RelapseMultiple MyelomaNCT04776330Chongqing Precision Biotech Co., Ltd80
招募中
1 期
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseNeoplasm, Plasma CellMultiple Myeloma in RelapseMultiple MyelomaNCT04271644Chongqing Precision Biotech Co., Ltd80
尚未招募
1 期
Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple MyelomaMultiple MyelomaNCT06705725Carbiogene Therapeutics Co. Ltd.38
招募中
2 期
A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple MyelomaNew Diagnosis TumorMultiple MyelomaNCT05712083Zhejiang University40